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Human islet amyloid polypeptide (hIAPP), a pancreatic islet protein of 37 amino acids, is the main component of islet amyloid,
seen at autopsy in patients with type 2 diabetes mellitus (DM2). To investigate the roles of hIAPP and islet amyloid in DM2,
we generated transgenic mice expressing hIAPP in their islet beta cells. In this study, we found that after a long-term, high-
fat diet challenge islet amyloid was observed in only 4 of 19 hIAPP transgenic mice. hIAPP transgenic females exhibited severe
glucose intolerance, which was associated with a downregulation of GLUT-2 mRNA expression. In isolated islets from hIAPP
males cultured for 3 weeks on high-glucose medium, the percentage of amyloid containing islets increased from 5.5% to 70%.
This ex vivo system will allow a more rapid, convenient, and speciﬁc study of factors inﬂuencing islet amyloidosis as well as of
therapeutic strategies to interfere with this pathological process.
Copyright © 2008 J. W. M. H¨ oppener et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Islet amyloid polypeptide (IAPP), also referred to as amylin,
is a 37 amino acid protein produced in the pancreatic
islet beta cells. Human IAPP (hIAPP) is implicated in the
pathophysiology of type 2 diabetes mellitus (DM2) since it
forms proteinaceous tissue deposits in the pancreatic islets
(“islet amyloid”) [1–3]. Islet amyloid has been demonstrated
in more than 80% of patients with DM2 [4, 5]. Islet amyloid
formation is implicated in development of beta cell failure
which, in addition to insulin resistance, is a characteristic
of DM2 [6]. Overproduction of IAPP in insulin resistance
mayoccurduetocommontranscriptionregulatoryelements
in the promoter regions of the IAPP and insulin genes [7],
and this might underly the enhanced amyloid formation in
DM2 [3]. This in turn may induce impairment of beta cell
function since aggregation of hIAPP has been demonstrated
tobecytotoxic[8–10].However,involvementofisletamyloid
in development of DM2 is still not ﬁrmly established. Recent
data, both for hIAPP and for other amyloidogenic proteins
(notably the Alzheimer’s disease-related Abeta peptide),
indicate that the degree of amyloid formation does not
correspond with the severity of disease [11, 12]. In addition,
preﬁbrillar aggregates of amyloidogenic proteins seem to
be more cytotoxic than mature amyloid ﬁbrils [13, 14]. To
explore the potential diabetogenic eﬀects of hIAPP and islet
amyloid, we have generated transgenic mice overproducing
biologically active hIAPP in the islet beta cells [15–17]2 Experimental Diabetes Research
(mouse IAPP does not form islet amyloid). We previously
showed that hIAPP overexpression in itself does not induce
hyperglycemia, hyperinsulinemia, or obesity in these mice
[15]. However, when the hIAPP transgenic mice were
crossbred with leptin-deﬁcient and insulin-resistant ob/ob
mice, extensive islet amyloid formation with worsening of
the diabetes was observed [18]. In the present paper, we
describe two experimental studies. In an in vivo experiment,
we examined the inﬂuence of transgenic hIAPP expression
on glucose tolerance of mice on a high-fat diet for a long
period of time. Previous studies had shown that long-term,
high-fat diet induces hyperglycemia, hyperinsulinemia, and
obesity in mice [19, 20]. Furthermore, high-fat diet may
be involved in islet amyloid formation in hIAPP transgenic
mice [21]. We, thus, administered a high-fat diet for 14
months to hIAPP transgenic and nontransgenic (control)
mice and report here the islet amyloid formation, glucose
tolerance, and islet GLUT-2 mRNA expression. In addition,
we describe the development of an ex vivo model system
for islet amyloidosis, using pancreatic islets isolated from
the hIAPP transgenic mice. When such islets were cultured
in high-glucose medium, amyloid formation occurs more
rapidly as compared to the in vivo situation. Thus, this
ex vivo model system will enable to study the process and
eﬀects of islet amyloid formation more speciﬁcally and
conveniently.
2. MATERIALS AND METHODS
2.1. Animals
The generation of C57Bl/6J hIAPP transgenic mice with a rat
insulin-2 gene promoter fragment (position −695 to +8 rel-
ative to the transcription start site) linked to the hIAPP gene
has previously been described [15]. The hIAPP transgenic
mice were maintained by breeding heterozygous transgenic
mice with mates of the C57BL/6J strain. Transgenic mice
were diﬀerentiated from nontransgenic (NT) littermates by
dot blot Southern hybridization, using a 588bp hIAPP-
speciﬁc DNA probe [15]. Mice were housed on hardwood
bedding in polypropylene cages and maintained in air-
conditioned rooms at 20–22◦C with a photoperiod of 12
hours light, 12 hours dark. Water was available contin-
uously and the mice received ad libitum a regular diet
until 2.5 months of age. This diet contained 4,500kcal/kg
and included 22.5% protein and 4.8% fat (Hope Farms,
Woerden, The Netherlands). At 2.5 months of age, the diet
was switched to a high-fat diet for 14 months containing
5,600kcal/kg,20.8%protein,and36.0%fat(30.0%cocoaoil,
6.0% corn oil; Hope Farms).
2.2. Glucosetolerancetest
At 14 months after the start of the high-fat diet, non-
fasted mice were anaesthetized with an i.p. injection
of midazolam (0.4mg/mouse) (Dormicum, Hoﬀman-La-
Roche, Basel, Switzerland), and a combination of ﬂuanison
(0.9mg/mouse), and fentanyl (0.02mg/mouse) (Hypnorm,
Janssen, Beerse, Belgium). D-glucose (British Drug Houses,
Poole, UK) was injected i.p. (1g/kg) and blood was sampled
from the retrobulbar, intraorbital, capillary plexus before
glucose administration and after10, 30, 60, and 120 minutes.
The samples were taken in heparinized tubes and stored
on ice. Following centrifugation, plasma was separated and
stored at −20◦C until analysis. After the 120-minute blood
sample, tissue was sampled (see below), and trunk blood
was obtained for measurement of IAPP levels. The blood was
collected in EDTA-tubes and kept on ice until centrifugation
at 1500g for 5 minutes at 4◦C. Plasma was stored at −80◦C.
All animal experiments were approved by the Animal
WelfareCommitteeofUtrechtUniversity/UniversityMedical
Center Utrecht, The Netherlands.
2.3. Plasmameasurements
IAPP levels were measured in 25–100ul plasma by RIA as
described [15], using a rabbit, polyclonal hIAPP antiserum
(K1338) that shows full cross-reactivity with synthetic
amidatedrat/mouseIAPP[22].Freeandboundradioactivity
was separated by use of double antibody immunoprecip-
itation. The sensitivity of the assay is 3.5pmol/l and the
coeﬃciency of variation <10% at both low and high levels.
Insulin levels were measured in 20ul plasma by RIA using
guinea pig anti-rat insulin antibody, 125I-labelled human
insulin as tracer and rat insulin as standard (Linco Research,
St. Charles, Mo, USA). Free and bound radioactivity was
separated by use of an anti-IgG antibody (Linco). The
sensitivity of the assay is 12pmol/l and the coeﬃciency of
variation <3% at both low and high levels. Glucose was
determined in 10ul plasma by the glucose oxidase method.
2.4. Histologicalanalysisofpancreatictissue
Pancreatic tissue samples were ﬁxed in 3.7% phosphate-
buﬀered formalin (pH 7.4) for 24–48 hours and paraﬃn
embedded. Sections of 5μm were stained with Congo
red for detection of islet amyloid by polarized light
microscopy (“apple-green” birefringence) and ﬂuorescence
lightmicroscopy(red-colouredautoﬂuorescence).Atleast10
isletspermousewereexamined.Thepercentageofindividual
islet areas occupied by amyloid, as indicated by Congo
red positive staining, was visually estimated and scored as
follows: 0% = score 0, between 0 and 26% = score 1, 26–
50% = score 2, 51–75% = score 3, and 76–100% = score 4.
The Amyloid Index (range: 0–100) of an individual mouse
was calculated as (1 × N1+2× N2+3× N3+4× N4) ×
25/n,w h e r eN1 is the number of islets with score 1, N2 the
number with score 2, and so on, and n is the total number
of islets investigated. The degree of islet amyloid formation
was determined with the investigator being unaware of the
genetic status of the animals (i.e., “blind”).
To examine the cellular expression of GLUT-2 mRNA,
paraﬃn sections were subjected to in situ hybridization
using a previously described protocol [23]a n da35S-labelled
oligonucleotideprobecoveringthenucleotidesequence247–
276 of mouse GLUT-2 cDNA [24]. In order to conﬁrm
beta cell expression of hIAPP mRNA in the transgenic mice,J. W. M. H¨ oppener et al. 3
sections were also hybridized with a 35S-labelled oligonu-
cleotide probe speciﬁc for hIAPP mRNA [25].
2.5. Imageanalysisandmorphometry
In situ hybridization radiolabelling was examined in a bright
ﬁeld microscope (Olympus, BX60), and images were cap-
tured with a digital camera (Olympus, DP50). To quantify
the density of labelling for GLUT-2 mRNA within islets,
areas of in situ hybridization radiolabelling were calculated.
Islets (n = 5–8 per animal) were randomly selected from
diﬀerent parts of the sections from 4 mice, 2 males and 2
females in each group. The transgenic mice analyzed were
rated as negative for amyloid. The labelled area, that is, grain
density within an islet, and total islet area were measured,
using NIH-image software, and the density of labelling was
expressed as percentage of the total islet area [23, 26]. All
sections used were hybridized simultaneously and under
identical conditions.
2.6. Isolationofpancreaticislets
For islet isolation, transgenic mice were bred to homozy-
gosity for the hIAPP transgenic locus. Homozygotes were
discriminated from heterozygous and nontransgenic litter-
mates by dot blot Southern hybridization of tail DNA
u s i n gah u m a n - s p e c i ﬁ cI A P Pp r o b e[ 15] and quantiﬁcation
of the hybridization signal using phosphor imaging and
Image-Quant software (Molecular Dynamics, Inc. Krefeld,
Germany).
Islets were isolated from the pancreas of 6-month-
old hIAPP transgenic male mice, essentially as previously
described [27]. Brieﬂy, under halothane anaesthesia, the
abdomen was opened. The pancreas was excised starting
from the spleen site to the duodenum. Subsequently, the
pancreas was brougth in 10mL sterile Krebs-Ringer-buﬀer
supplementedwith25mmol/LHepes(KRH)andcontaining
10% Bovine Serum Albumin (BSA) at 4◦C. Next, the
pancreaswaschopped,digestedusingatwo-stageincubation
of 20 minutes at 37◦C with successively 1.0 and 0.7mg/mL
collagenase (Sigma type XI, Sigma, St Louis, MO, USA).
Islets were separated from exocrine tissue by centrifugation
over a discontinuous dextran gradient [28] and further puri-
ﬁed by handpicking into 9cm petridishes with 12mL KRH
buﬀer, pH = 7.4, supplemented with 10% BSA penicillin
(100units/mL)/streptomycin (0.1mg/mL) (KRH 10% BSA
P/S)andglucosetoaconcentrationof11mM.Twodaysafter
isolation, the islets from 12 mice were pooled, mixed and
split into portions. Four portions of 75 islets each were ﬁxed
and embedded for amyloid quantiﬁcation. Eight portions of
approximately 90 islets were transferred to culture medium
with 28mM glucose. Medium was changed every 2-3 days,
switching between 11mM and 28mM of glucose (to prevent
possibledesensitizationofthebetacells).Isletswerecounted,
while being picked into the dishes with fresh medium. At 3
weeks after islet isolation, the cultured islets were ﬁxed and
embedded for amyloid quantiﬁcation.
2.7. Fixationandembeddingofpancreaticislets
Isletswerewashedwithphosphatebuﬀeredsaline(PBS),and
ﬁxed in 0.5mL islets ﬁxative (2% paraformaldehyde, 0.2%
glutaraldehyde in 0.1M S¨ orensen buﬀe r )f o r2ho ur satr oo m
temperature. Fixative was removed and islets were washed
with 0.5mL 0.1M S¨ orensen buﬀer. S¨ orensen buﬀer was
removed and islets were resuspended in 30μl3 7 ◦Ch e a t e d
12% gelatin, cooled on ice and stored at −20◦C.
2.8. Amyloidquantiﬁcationinculturedislets
Fromthegelatin-embeddedisletblocks,5μmfr ozensections
were cut onto Superfrost Plus microscope slides (Menzel-
Gl¨ aser) and stored at −20◦C until further use. Sections were
ﬁxedinacetonefor1 ,reh ydratedinPBSfor15
 ,stainedwith
heamatoxylin for 1 , washed in running tap water for 5 ,a n d
stained with Congo red (1g/liter saturated sodium chloride
80% ethanol, into which 10mL/liter 1% sodium hydroxide
was added just before staining) for 30
 . After dehydration
in an augmenting ethanol series (70%, 96%, 100%) and
xylene (twice), sections were enclosed with Depex. Amyloid-
containing paraﬃn sections of hIAPP transgenic mouse
pancreatic tissue were used as positive control for the Congo
red staining.
For the detection of amyloid, Congo red-stained islet
sections were examined using a ﬂuorescence microscope.
Amyloid deposits were visible as bright red autoﬂuorescent
areas without cells, which showed a green birefringence
upon visualization with polarized light. An islet was scored
as amyloid positive if at least 2 successive sections of that
islet contained Congo red-positive amyloid deposits. The
scoring was performed in a “blind” fashion, that is, with the
investigator unaware of the source of the islets.
2.9. Statisticalanalysis
Values are means ±SEM, unless stated otherwise. P-values
indicate the probability level of random diﬀerence between
groups, or of random correlation, respectively. P-values
<.05 were considered to represent statistical signiﬁcance.
Nonparametric T-tests were used to compare 2 independent
samples (Mann-Whitney-U test: hIAPP versus NT, male
versus female). Data of the mRNA in situ hybridizations
were analyzed by Student’s unpaired t-test. Diﬀerences in
percentage of amyloid-positive islets between 2 days and 3
weeks of culture were analyzed by use of one-way analysis of
variance (ANOVA). Probability values of less than .01 were
considered signiﬁcant.
3. RESULTS
3.1. BodyweightandplasmaIAPPlevels
Body weight after 14 months on the high-fat diet did not
diﬀer between the groups, being 57 ± 0.8g versus 58 ± 0.9g
in male hIAPP (n = 8) and NT (n = 5) mice, and 59 ±
1.1g versus 64 ± 3g in female hIAPP (n = 11) and NT
(n = 6) mice. Plasma IAPP levels were 462 ± 78pmol/L in
male hIAPP mice versus 195 ± 32pmol/L in male NT mice,4 Experimental Diabetes Research
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Figure 1: Plasma insulin and glucose levels immediately before and at diﬀerent timepoints after an intraperitoneal injection of glucose
(1g/kg body weight) in anaesthetized, nonfasted nontransgenic (NT, dotted line), and hIAPP transgenic mice (solid line) on a high-fat diet
for 14 months. Mean values and SEM are shown; n = 5–11 per group of mice; statistically signiﬁcant changes between hIAPP and NT mice
are indicated by ∗(P < .05) and ∗∗(P < .01).
and 346 ± 81pmol/L in female hIAPP mice versus 130 ±
21pmol/L in female NT mice, being signiﬁcantly higher in
hIAPP mice of both genders (P < .01) without any gender
diﬀerence.
3.2. Glucosetolerancetest
After 14 months on the high-fat diet, nonfasted plasma
glucose and insulin levels were not diﬀerent between hIAPP
and NT mice of the same gender. However, both for the
hIAPP and NT mice, plasma insulin levels were higher in
m a l e sa sc o m p a r e dt of e m a l e s( Figure 1). When glucose was
administered i.p. (1g/kg), the insulin response to glucose
and the glucose elimination were similar in hIAPP and
NT male mice. In contrast, in female hIAPP mice, plasma
glucose levels after the i.p. glucose challenge were markedly
higher at all time points as compared to female NT mice
(P < .05 or P < .01) in association with increased insulin
levels 30 minutes after glucose administration (P < .01).
Hence, hIAPP overproduction was associated with severe
impairment of glucose elimination in female but not in male
mice after high-fat diet.
3.3. Pancreaticisletamyloidformation
Islet amyloid was detected in 4/19 hIAPP mice on high-fat
diet but in none of the 11 NT mice. The Amyloid Index for
these 4 mice was 11.0 ± 6.2 (average and SD). There was
no gender diﬀerence in islet amyloid formation in hIAPP
transgenic mice (3/8 in males versus 1/11 in females).
3.4. IsletGLUT-2mRNAexpression
As expected, a strong hIAPP mRNA labeling was observed
in the islets of all transgenic mice, while it was lacking in
a l lN Tm i c e( F i g u r e s2(a), 2(b)). GLUT-2 mRNA labeling of
weak to moderate density was observed in the islets of NT
mice (Figure 2(c)), with no overt diﬀerence between female
and male mice. In the transgenic mice, however, the GLUT-
2 mRNA labeling was generally weaker, and even barely
detectable in some female mice (Figure 2(d)). The GLUT-2
mRNA signal was reduced in all transgenic mice, regardless
of the presence or absence of islet amyloid. Image analysis
revealedasigniﬁcantreductionofGLUT-2mRNAlabelingof
islets in hIAPP transgenic versus NT mice (P = .02, Figure 3).
3.5. Exvivosurvivalandamyloidformationin
culturedhIAPPtransgenicpancreaticislets
The percentage of 3-week survival of hIAPP transgenic islets
was 83.8 ± 1.0% (n = 8). Of all islet cultures, 22–30 islets
were scored for the presence of amyloid. The percentage of
amyloid-positiveisletssigniﬁcantlyincreased(P<.001)from
5.5±3.4%(n = 4)after2daysofcultureto70 ±3.1%(n = 8)
at the end of the culture period. Thus, the percentage of
amyloid-positive islets increased more than 10 times in three
weeks of culture at high glucose conditions in this ex vivo
islet amyloidosis system. An example of a cultured hIAPP
transgenic islet containing amyloid is shown in Figure 4.J. W. M. H¨ oppener et al. 5
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Figure 2: In situ mRNA hybridization (using radiolabeled oligoprobes) for hIAPP (a), (b), and GLUT-2 (c), (d) in islets of nontransgenic
(a), (c), and hIAPP transgenic (b), (d) female mice after 14 months on high-fat diet. Note that hIAPP mRNA expression is absent in the
nontransgenic islet, and that GLUT-2 mRNA expression is reduced in the transgenic islet. Scale bar = 30μm.
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Figure 3: Comparison of the average labeling density of GLUT-2
mRNA in situ hybridization in pancreatic islets from nontransgenic
(NT) and hIAPP transgenic (hIAPP) mice (P = .02). For both
groups 4 mice were analysed, 2 males, and 2 females. The 4
transgenic mice did not have amyloid.
4. DISCUSSION
4.1. High-fatdietandamyloidformation
In this study, transgenic mice overproducing the amyloido-
genic hIAPP in their pancreatic islet beta cells, as well as
NT control mice, were fed a high-fat diet for 14 months, in
order to evaluate the impact on islet amyloid formation and
glucose homeostasis when combining these two potentially
diabetogenic factors. We anticipated a marked islet amyloid
formation in the hIAPP transgenic mice on the high-fat
diet because we previously observed that crossbreeding
the hIAPP transgenic mice with the Obese mouse (being
severly insulin resistant) resulted in extensive islet amyloid
formation [18]. Also, when insulin resistance was induced in
hIAPP mice by crossbreeding with the obese Agouti viable
yellow mice [29] or by exogenous growth hormone and
glucocorticoids [30], islet amyloid formation was promoted.
Inaddition,high-fatfeedinginducedisletamyloidformation
(a) (b)
Figure 4: Detection of islet amyloid in islet of Langerhans isolated
from an hIAPP transgenic mouse, and cultured in medium with a
high glucose concentration. Frozen section of a gelatine-embedded
islet was stained with the amyloid-speciﬁc dye Congo red and
visualized with light microscopy (a) and ﬂuorescence microscopy
(b), respectively.
in approximately 80% of male mice in another hIAPP
transgenic colony [21]. However, we found that only four
out of the 19 hIAPP mice (approx. 40% of the males)
that were followed for 14 months on the high-fat diet
did develop islet amyloid. This lower frequency might be
due to diﬀerences in the genetic background and/or the
composition of the diet, inﬂuencing insulin resistance and
IAPP expression. The amyloid index in those four high-fat
fed mice was higher than in six of 33 similarly aged hIAPP
mice (approx. 30% of the males) which developed amyloid
on a regular diet (11.0 ± 6.2v e r s u s4 .2 ± 2.9, P = .024)
[18]. This indicates that although long-term, high-fat diet
indeed has the capacity to promote islet amyloid formation
in these hIAPP transgenic mice, the eﬃciency is not high.
Crossbreeding the hIAPP mice with leptin-deﬁcient Obese
mice introduced more severe obesity and insulin resistance
[18] as compared to the high-fat diet. Consequently, these
other factors seem of importance for the promotion of islet
amyloid formation. Another factor might be hyperglycemia,
which is more severe in the hIAPP ob/ob mice as compared
to the hIAPP mice on high-fat diet. Such a hypothesis is
supported by the ﬁnding that in isolated pancreatic islets
of our hIAPP mice, islet amyloid was detected by electron
microscopy after culture in high-glucose medium but not in
low-glucose medium [31]. Other mechanisms may, however,
also be of importance.6 Experimental Diabetes Research
4.2. Highfatdietandglucosetolerance
In this study, we also observed severe glucose intolerance in
female but not in male hIAPP transgenic mice. The ﬁnding
thatinallgroupsofmiceplasmainsulinlevelsfailedtoreturn
to basal within 2 hours after the glucose load is in accordance
with high-fat diet inducing insulin resistance [32]. Also,
the higher insulin levels in male mice versus female mice
is well known from previous studies [33]. Thus, our data
indicate that the overproduction of insulin in response to
insulin resistance after high-fat diet was adequate in hIAPP
males but not in hIAPP females. Since there was no gender
diﬀerence in the amyloid formation in high-fat fed hIAPP
mice, these results suggest that a metabolic impact of high
levels of circulating IAPP underlies the gender diﬀerence in
glucose tolerance of hIAPP transgenic mice after high-fat
diet. IAPP has, thus, been shown to inhibit insulin secretion
[34, 35] as well as to inhibit glycogen synthesis in rat muscle
tissue [36] through inhibition of glycogen synthase and
stimulation of glycogen phosphorylase [37]. In addition, it
has been observed that IAPP administration induces insulin
resistance in rats [38], although no such eﬀect was evident in
humans [39]. IAPP has also in some studies [40]b u tn o ti n
others [41] been shown to increase liver glucose production.
Whether these actions show gender diﬀerences, and thus
may explain the remarkable glucose intolerance observed in
female but not in male hIAPP transgenic mice on the high-
fat diet, is not known. Indeed, it is striking that although
male rodents generally are more prone to insulin resistance
than females, the hIAPP transgenic females on high-fat diet
are more glucose intolerant than their male littermates. Since
insulin levels are not lower in the hIAPP females compared
to the NT females, these data suggest that insulin sensitivity
is impaired in the female hIAPP mice.
4.3. High-fatdietandGLUT-2expression
Islet GLUT-2 mRNA expression was reduced in hIAPP
transgenic versus NT mice, and this reduction appeared
more severe in female than in male mice. Beta cell GLUT-2
expression is known to correlate with glucose responsiveness
of the cells [42]. However, insulin levels were not reduced in
the male or female hIAPP mice. Therefore, it is presently not
known if and how the reduced GLUT-2 mRNA expression
among the transgenic mice might be related to the glucose
intolerance in the female hIAPP mice. Also, the mechanism
of hIAPP mediated downregulation of islet GLUT-2 mRNA
expressionisunknown,butourdataindicatethatinaddition
to inhibition of insulin action in muscle [33, 34]I A P Pc a n
(in) directly inhibit glucose responsiveness of islet beta cells
by aﬀecting GLUT-2 expression.
In conclusion, this in vivo study shows that promoting
insulin resistance over a long period of time by giving a
high-fatdietfor14monthspromotesisletamyloidformation
in hIAPP transgenic mice, although less extensively than
in the severe insulin-resistant Obese, leptin-deﬁcient hIAPP
mice. This suggests that the degree of insulin resistance is
important for extensive development of islet amyloid. In
addition, we observed a remarkable gender diﬀerence in
that severe glucose intolerance was observed only in female
hIAPP transgenic mice given high-fat diet and not in males.
We suggest that this gender diﬀerence is due to the high level
of circulating IAPP rather than to islet amyloid formation.
If and how this glucose intolerance might be mediated by
downregulation of beta cell GLUT-2 gene expression, as
observed in the hIAPP mice, is presently unknown.
4.4. Exvivoisletamyloidosismodel
The rationale for the ex vivo study was to examine if
amyloidwouldbeformedinisolatedandculturedpancreatic
islets from hIAPP mice, to such a degree that it would be
detectable with light microscopy. Since both the present and
previous [18] in vivo data indicated the development of
islet amyloid notably in male hIAPP mice, we decided to
investigate amyloid formation in such islets speciﬁcally from
male mice. To increase the potential for amyloid formation,
we bred the mice to homozygosity for the hIAPP transgene.
At an age of 6 months, homozygous transgenic hIAPP
males had islet amyloid in about 5% of their pancreatic
islets, at 2 days after islet isolation. Previously, we detected
amyloid ﬁbrils by electron microscopy in islets from 4–10
months old heterozygous hIAPP transgenic mice, cultured
for 1 week in medium with 11 or 28mM glucose [31].
With the present model, using islets from 6-month-old
homozygous hIAPP transgenic males, cultured in medium
with high glucose (switching between 11 and 28mM), we
can detect amyloid deposits with Congo red staining and
light microscopy, thus enabling quantiﬁcation of the degree
of islet amyloidosis. The number of amyloid-positive islets
increased more than 10 fold (from 5.5 to 70%) after 3
weeks of culture in medium containing a high glucose
concentration. Although an accurate comparison between
thedegreesofisletamyloidformationinvivoandexvivowas
not made, our data certainly indicate stronger islet amyloid
formation in hIAPP islets cultured ex vivo as compared
to in vivo. This might be explained by the higher glucose
concentrations in the ex vivo system. hIAPP transgenic
mice in vivo have normal plasma glucose concentrations
[15, 18], whereas ex vivo the glucose concentration in the
medium switched between 11 and 28mM. It is known
that a high glucose concentration triggers both insulin
and IAPP secretion, and the hIAPP transgene is under
control of an insulin promoter. In addition, macrophages
have been implicated in in vivo removal of (beginning)
amyloid deposits [43] and such macrophages are absent in
the ex vivo system, potentially allowing increased amyloid
formation. When combined with a more accurate amyloid
quantiﬁcation procedure involving image analysis, this ex
vivosystemmaypresentafastandconvenientmodeltostudy
the process (and factors involved) of islet amyloidosis, as
well as the detrimental consequences for individual beta cells
(apoptosis) and islet function (insulin producing capacity).
In addition, such a model system might be used as an
amyloidosis assay to assess the potency of known and novel
therapeuticstrategies,aimedatreducing,orevenpreventing,
islet amyloid formation, and its eﬀects on beta cell and islet
function.J. W. M. H¨ oppener et al. 7
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